Visit https://www.peervoice.com/BFW860 to view the entire programme with slides. After completing “Evaluating the Evidence for SGLT2 Inhibition in CKD: Highlights From the 2021 Virtual ERA-EDTA Congress”, participants will be able to: Describe key safety and efficacy data on SGLT2 inhibition for the management of chronic kidney disease (CKD); Summarise what the latest data on SGLT2 inhibition add to the current treatment algorithm for CKD; Discuss the clinical implications of SGLT2 inhibition in the context of managing patients with CKD.